ICON Stock Soars 13%, Adding $1.8 Billion After Third-Quarter Results And Bigger Buyback
The contract research firm trimmed its 2026 revenue outlook, yet its shares hit a 52-week high as the buyback grew to $750.0 million.
ICON, which runs outsourced drug and device trials for drugmakers and biotech clients, saw its shares climb 12.60% to $206.04 in Wednesday trading, as of 9:53 a.m. ET, a 52-week high that added about $1.8 billion in market value. The move came the day after the company reported third-quarter revenue of $2,024.8 million and cut its 2026 revenue outlook.
Lower revenue guidance, bigger buyback
The company now expects 2026 revenue of $8,100 million to $8,200 million and adjusted earnings of $10.35 to $10.65 per share, according to its earnings release.
Adjusted earnings for the quarter came to $2.66 per share. The board expanded the buyback authorization to $750.0 million, and net business wins were $3,150 million, the company said.
The quarter was a split picture. Adjusted EBITDA fell 13.1% from a year earlier but grew 3% from the prior quarter, the company said. Backlog of contracted work stood at $24.5 billion as of September 30.
Management also said it repurchased $400.0 million of stock at an average price of $170 per share, well below Wednesday's level.
A 2027 sketch from the CEO
On the earnings call, CEO Barry Balfe floated mid-single-digit revenue growth for 2027, while saying formal guidance will come with fourth-quarter results.
ICON, which employed about 40,100 people in 97 locations across 55 countries at the end of 2025, offers clinical development across Phases I-IV, laboratory testing and consulting. Europe supplied 57.9% of its 2025 revenue, and the United States 30.6%.
A big day after a flat year
Before Wednesday, ICON shares were up about 0.4% for the year as of Tuesday's close, trailing the S&P 500's gain of about 13%.
The stock was on pace for its biggest one-day gain since May 28, when it rose 15.5%. Its market value was about $15.9 billion at the time of the report.
Formal 2027 guidance is due with fourth-quarter results, the CEO said.
Sources
- Icon Non-GAAP EPS of $2.66 beats by $0.03, revenue of $2.02B beats by $10M (NASDAQ:ICLR) | Seeking Alpha — seekingalpha.com
- Icon PLC (ICLR) Q3 Earnings and Revenues Beat Estimates — Yahoo Finance
- ICON Reports Third Quarter 2026 Results – Company Announcement - FT.com — Financial Times
- Icon Q3 2026 earnings preview (ICLR:NASDAQ) | Seeking Alpha — seekingalpha.com
- ICON Cuts 2026 Revenue Guidance To $8.1 Billion-$8.2 Billion As Third-Quarter Adjusted EBITDA Falls 13.1% — SEC filing